Patents by Inventor Han-Zhong Zhang

Han-Zhong Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7732468
    Abstract: Disclosed are 3-aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds thereof, represented by the Formula I: wherein Ar1, Ar2, and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: June 8, 2010
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Nilantha Sudath Sirisoma, Han-Zhong Zhang
  • Patent number: 7622497
    Abstract: The present invention is directed to novel derivatives of gambogic acid and analogs thereof. The present invention also relates to the discovery that novel derivatives of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: November 24, 2009
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Songchun Jiang, Han-Zhong Zhang
  • Patent number: 7592143
    Abstract: The present invention relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using Apoptosis Inducing Proteins (AIPs) as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogeneous binding assays using purified or partially purified AIPs; or whole cell assays using cells with altered levels of one or more AIPs. The invention also contemplates use of gambogic acid or GA-related compounds which bind AIPs and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled GA is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: September 22, 2009
    Assignee: Cytovia, Inc.
    Inventors: Shailaja Kasibhatla, Sui Xiong Cai, Ben Tseng, Katayoun Alavi Jessen, Nicole Marion English, Serguei Maliartchouk, Songchun Jiang, Nilantha Sudath Sirisoma, Han-Zhong Zhang, Jared Kuemmerle
  • Patent number: 7504382
    Abstract: Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing or reducing the replication of coronavirus, or picornaviruses, with the compounds of the present invention.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: March 17, 2009
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, William E. Kemnitzer, Hong Zhang, Han-Zhong Zhang
  • Publication number: 20080300191
    Abstract: Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses.
    Type: Application
    Filed: May 6, 2004
    Publication date: December 4, 2008
    Inventors: Sui Xiong Cai, William E. Kemnitzer, Hong Zhang, Han-Zhong Zhang
  • Patent number: 7435750
    Abstract: The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: October 14, 2008
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, John A. Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Jared Daniel Kuemmerle, Kristin P. Ollis
  • Publication number: 20080113946
    Abstract: Disclosed are N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs thereof, represented by the Formula I: wherein Ar, A, Q and R1-R6 are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: November 14, 2007
    Publication date: May 15, 2008
    Applicant: Cyntovia, Inc.
    Inventors: Han-Zhong Zhang, Sui Cai, William Kemnitzer
  • Publication number: 20080113984
    Abstract: Disclosed are 3-aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds thereof, represented by the Formula I: wherein Ar1, Ar2, and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: November 15, 2007
    Publication date: May 15, 2008
    Applicant: Cytovia, Inc.
    Inventors: Sui Cai, John Drewe, Nilantha Sirisoma, Han-Zhong Zhang
  • Publication number: 20080045514
    Abstract: Disclosed are 3-aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs thereof, represented by the Formula I: wherein Ar1, Q2, R1, R2, dashed line and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: July 18, 2007
    Publication date: February 21, 2008
    Applicant: Cytovia, Inc.
    Inventors: Sui Cai, John Drewe, Han-Zhong Zhang, Shailaja Kasibhatla, Gisela Claassen, Nilantha Sirisoma, William Kemnitzer
  • Patent number: 7317029
    Abstract: Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, R2, A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: January 8, 2008
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, Jared D. Kuemmerle, Hong Zhang, William E. Kemnitzer
  • Publication number: 20070253957
    Abstract: The present invention is directed to substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs thereof, represented by the general Formula (I): wherein Q, Y, Z, R4-R7, X and Ar are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: October 6, 2005
    Publication date: November 1, 2007
    Applicant: Cytovia, Inc.
    Inventors: Han-Zhong Zhang, Sui Cai, John Drewe
  • Patent number: 7270801
    Abstract: The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: September 18, 2007
    Assignee: Cytovia, Inc.
    Inventors: Eckard Weber, Sui Xiong Cai, John F. W. Keana, John A. Drewe, Han-Zhong Zhang
  • Publication number: 20070112003
    Abstract: Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, R2, A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: November 6, 2006
    Publication date: May 17, 2007
    Applicant: Cytovia, Inc.
    Inventors: Sui Cai, Han-Zhong Zhang, Jared Kuemmerle, Hong Zhang, William Kemnitzer
  • Publication number: 20070099877
    Abstract: Disclosed are N-aryl-thienopyrimidin-4-amines and analogs thereof, represented by the Formulae I-II: wherein Ar and R1-R4 are defined herein. The present invention relates to the discovery that compounds having Formulae I-II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: November 2, 2006
    Publication date: May 3, 2007
    Applicant: Cytovia, Inc.
    Inventors: Sui Cai, William Kemnitzer, Nilantha Sirisoma, Han-Zhong Zhang
  • Publication number: 20070093456
    Abstract: The present invention is directed to novel derivatives of gambogic acid and analogs thereof. The present invention also relates to the discovery that novel derivatives of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: December 17, 2004
    Publication date: April 26, 2007
    Inventors: Sui Cai, Songchun Jiang, Han-Zhong Zhang
  • Patent number: 7176234
    Abstract: The present invention is directed to derivatives of gambogic acid and analogs thereof. Exemplary gambogic acid derivatives of the present invention include, among others, derivatives substituted in the C10 and C28 positions of gambogic acid. The present invention also relates to the discovery that certain preferred compounds of the present invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: February 13, 2007
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Shailaja Kasibhatla, Kristin P. Ollis, Han-Zhong Zhang, John A. Drewe, Ben Tseng, Nilantha Sudath Sirisoma
  • Patent number: 7144876
    Abstract: Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, R2, A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: December 5, 2006
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, Jared D Kuemmerle, Hong Zhang, William E Kemnitzer
  • Patent number: 7135480
    Abstract: The present invention is directed to substituted 1-benzoyl-3-cyano-pyrrolo[1,2-?]quinolines and analogs thereof, represented by the general Formula I: wherein R1–R8, L, Q, dash line and Ar are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: November 14, 2006
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A Drewe, Sungchun Jiang, Shailaja Kasibhatla, Jared Daniel Kuemmerle, Nilantha Sudath Sirisoma, Han-Zhong Zhang
  • Patent number: 7074813
    Abstract: The present invention is directed to substituted N?-(arylcarbonyl)-benzhydrazides, N?-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: wherein Ar1, Ar2, and R1–R2 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: July 11, 2006
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Shailaja Kasibhatla, John Drewe, P. Sanjeeva Reddy, Han-Zhong Zhang
  • Patent number: 7041685
    Abstract: The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: May 9, 2006
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, John A. Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Jared Daniel Kuemmerle, Kristin P. Ollis